Nothing Special   »   [go: up one dir, main page]

LTC2822953I2 - Makrocikliniai dariniai, skirti proliferacinių ligų gydymui - Google Patents

Makrocikliniai dariniai, skirti proliferacinių ligų gydymui

Info

Publication number
LTC2822953I2
LTC2822953I2 LTPA2019519C LTPA2019519C LTC2822953I2 LT C2822953 I2 LTC2822953 I2 LT C2822953I2 LT PA2019519 C LTPA2019519 C LT PA2019519C LT PA2019519 C LTPA2019519 C LT PA2019519C LT C2822953 I2 LTC2822953 I2 LT C2822953I2
Authority
LT
Lithuania
Prior art keywords
treatment
proliferative diseases
macrocyclic derivatives
macrocyclic
derivatives
Prior art date
Application number
LTPA2019519C
Other languages
English (en)
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48142828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2822953(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of LTPA2019519I1 publication Critical patent/LTPA2019519I1/lt
Publication of LTC2822953I2 publication Critical patent/LTC2822953I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTPA2019519C 2012-03-06 2019-10-18 Makrocikliniai dariniai, skirti proliferacinių ligų gydymui LTC2822953I2 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607485P 2012-03-06 2012-03-06
US201361759307P 2013-01-31 2013-01-31
PCT/IB2013/051391 WO2013132376A1 (en) 2012-03-06 2013-02-20 Macrocyclic derivatives for the treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
LTPA2019519I1 LTPA2019519I1 (lt) 2019-11-11
LTC2822953I2 true LTC2822953I2 (lt) 2020-12-28

Family

ID=48142828

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP13717555.0T LT2822953T (lt) 2012-03-06 2013-02-20 Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
LTPA2019519C LTC2822953I2 (lt) 2012-03-06 2019-10-18 Makrocikliniai dariniai, skirti proliferacinių ligų gydymui

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP13717555.0T LT2822953T (lt) 2012-03-06 2013-02-20 Makrocikliniai dariniai, skirti proliferacinių ligų gydymui

Country Status (46)

Country Link
US (2) US8680111B2 (lt)
EP (1) EP2822953B9 (lt)
JP (2) JP5823066B2 (lt)
KR (1) KR101692600B1 (lt)
CN (1) CN104169286B (lt)
AP (1) AP2014007881A0 (lt)
AR (1) AR090230A1 (lt)
AU (1) AU2013229173B2 (lt)
BR (1) BR112014022106B1 (lt)
CA (1) CA2863892C (lt)
CL (1) CL2014002084A1 (lt)
CO (1) CO7061081A2 (lt)
CR (1) CR20140370A (lt)
CY (2) CY1118771T1 (lt)
DK (1) DK2822953T5 (lt)
DO (1) DOP2014000188A (lt)
EA (1) EA026155B9 (lt)
ES (1) ES2621220T3 (lt)
FR (1) FR19C1062I2 (lt)
GE (1) GEP201606560B (lt)
GT (1) GT201400187A (lt)
HK (1) HK1199247A1 (lt)
HR (1) HRP20170287T2 (lt)
HU (2) HUE034118T2 (lt)
IL (1) IL234062A (lt)
LT (2) LT2822953T (lt)
LU (1) LUC00131I2 (lt)
MD (1) MD4590C1 (lt)
ME (1) ME02630B (lt)
MX (1) MX350844B (lt)
MY (1) MY169142A (lt)
NI (1) NI201400102A (lt)
NL (1) NL301006I2 (lt)
NO (1) NO2019034I1 (lt)
NZ (1) NZ627900A (lt)
PE (1) PE20142339A1 (lt)
PH (1) PH12014501992B1 (lt)
PL (1) PL2822953T3 (lt)
PT (1) PT2822953T (lt)
RS (1) RS55814B1 (lt)
SG (1) SG11201404451TA (lt)
SI (1) SI2822953T1 (lt)
TW (1) TWI476199B (lt)
UY (1) UY34657A (lt)
WO (1) WO2013132376A1 (lt)
ZA (1) ZA201406244B (lt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2953931T (pt) 2013-01-31 2017-06-14 Vertex Pharma Piridona amidas como moduladores dos canais de sódio
CA2916605C (en) 2013-06-28 2018-04-24 Pfizer Inc. Solid forms of a macrocyclic kinase inhibitor
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
JP6463580B2 (ja) 2013-12-13 2019-02-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ
US9714258B2 (en) 2014-01-24 2017-07-25 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
CN103772272A (zh) * 2014-03-04 2014-05-07 定陶县友帮化工有限公司 2-boc-氨基-3-羟基-5-溴吡啶的合成方法
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
US10159663B2 (en) * 2014-08-20 2018-12-25 Teligene Ltd. Substituted macrocycles useful as kinases inhibitors and methods of use thereof
US9663535B2 (en) * 2014-10-13 2017-05-30 Atrin Pharmaceuticals LLC Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors
CA2969540C (en) 2014-12-02 2023-03-21 Ignyta, Inc. Combinations for the treatment of neuroblastoma
EP3246047A4 (en) * 2015-01-16 2018-08-22 Chugai Seiyaku Kabushiki Kaisha Combination drug
KR102599788B1 (ko) 2015-07-02 2023-11-07 터닝 포인트 테라퓨틱스, 인크. 단백질 키나제의 조절물질로서 키랄 디아릴 매크로사이클
MX2017017081A (es) 2015-07-06 2018-08-16 Tp Therapeutics Inc Polimorfo de macrociclo de diarilo.
DK3325488T3 (da) 2015-07-21 2020-09-14 Turning Point Therapeutics Inc Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer
SI3798222T1 (sl) * 2015-07-31 2024-02-29 Pfizer Inc. Kristalna oblika proste baze lorlatiniba
WO2017058780A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
JP7061068B2 (ja) 2015-12-18 2022-04-27 イグナイタ インコーポレイテッド 癌治療のための併用薬
WO2017148325A1 (zh) * 2016-03-03 2017-09-08 深圳市塔吉瑞生物医药有限公司 一种大环化合物及包含该化合物的组合物
CN105646355A (zh) * 2016-04-07 2016-06-08 戊言医药科技（上海）有限公司 3-(羟甲基)-1-甲基-吡唑-5-甲腈的制备方法
CN105732355A (zh) * 2016-04-07 2016-07-06 戊言医药科技（上海）有限公司 1-(5-氟-2-碘苯基)乙酮的制备方法
WO2017175091A1 (en) 2016-04-08 2017-10-12 Pfizer Inc. Crystalline forms of lorlatinib maleate
US10301324B2 (en) 2016-04-12 2019-05-28 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use
CN105801603B (zh) * 2016-04-13 2018-10-02 成都倍特药业有限公司 一种具有大环结构的alk抑制剂及其制备方法
EP3490564A4 (en) 2016-07-28 2020-02-26 Turning Point Therapeutics, Inc. MACRO CYCLE Kinase Inhibitors
JP6890179B2 (ja) * 2016-12-02 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二環式アミド化合物及びその使用方法
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018137679A1 (en) * 2017-01-25 2018-08-02 Teligene Ltd Process for the Preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
CA3068350A1 (en) 2017-06-30 2019-01-03 Bayer Animal Health Gmbh New azaquinoline derivatives
CN110913842A (zh) 2017-07-19 2020-03-24 伊尼塔公司 包括恩曲替尼的药物组合物
PT3658148T (pt) 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
ES2952985T3 (es) * 2017-10-10 2023-11-07 Pfizer Forma cristalina de hidrato de base libre de lorlatinib
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
BR112020012319A2 (pt) 2017-12-19 2020-11-24 Turning Point Therapeutics, Inc. compostos macrocíclicos para tratar doença
US20190343817A1 (en) 2018-02-12 2019-11-14 Vertex Pharmaceuticals Incorporated Method of treating pain
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
EP3784675A1 (en) 2018-04-23 2021-03-03 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
CN111918868B (zh) * 2018-05-04 2022-12-30 正大天晴药业集团股份有限公司 作为蛋白激酶调节剂的二芳基大环化合物
CN108621206B (zh) * 2018-05-07 2020-08-14 昆山国显光电有限公司 手套箱系统以及手套箱系统的保养方法
CN112703001A (zh) * 2018-09-18 2021-04-23 株式会社益力多本社 使用喹啉羧酰胺衍生物的癌症联用疗法
CN109232607A (zh) * 2018-09-20 2019-01-18 沈阳药科大学 劳拉替尼的合成方法
CN109081810A (zh) * 2018-09-20 2018-12-25 沈阳药科大学 1-甲基-3–((甲氨基)甲基)-1h-吡唑-5-腈的合成方法
JP7347852B2 (ja) * 2018-11-28 2023-09-20 深▲チェン▼市塔吉瑞生物医薬有限公司 重水素化大環状化合物の調製方法
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN109651397A (zh) * 2019-01-25 2019-04-19 安庆多辉生物科技有限公司 一种劳拉替尼中间体及制备劳拉替尼的方法
CN109651398B (zh) * 2019-01-25 2021-07-30 安庆多辉生物科技有限公司 一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法
CN109651418A (zh) * 2019-01-25 2019-04-19 安庆多辉生物科技有限公司 一种劳拉替尼原料药合成中间体及有机金属钯催化偶联制备劳拉替尼的方法
CN111499514B (zh) * 2019-01-31 2024-09-20 连云港润众制药有限公司 一种罗沙司他中间体的制备方法
EP3941457A4 (en) 2019-03-21 2023-04-26 Merck Sharp & Dohme LLC HISTONE-DEACETYLASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF HIV INFECTION
WO2020228747A1 (en) * 2019-05-14 2020-11-19 Teligene Ltd Substituted macrocycles useful as kinase inhibitors
EP3999514A1 (en) * 2019-07-18 2022-05-25 Pliva Hrvatska D.O.O. Crystalline lorlatinib : fumaric acid and solid state form thereof
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
CN110483551B (zh) * 2019-08-30 2021-10-22 北京赛思源生物医药技术有限公司 一种劳拉替尼游离碱的晶体
WO2021069571A1 (en) 2019-10-10 2021-04-15 Sandoz Ag Polymorph of lorlatinib
CN112812128B (zh) * 2019-11-18 2024-04-02 正大天晴药业集团股份有限公司 作为alk和ros调节剂的大环化合物
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
CN111170908B (zh) * 2020-01-09 2021-08-17 北京印刷学院 一种2，4-二甲基-3-甲磺酰基卤苯的合成方法
US20230117684A1 (en) 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
MX2022013657A (es) 2020-05-05 2023-02-01 Nuvalent Inc Quimioterápicos de éter macrocíclico heteroaromático.
PE20230309A1 (es) * 2020-05-05 2023-02-14 Nuvalent Inc Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos
US20230174554A1 (en) * 2020-05-18 2023-06-08 Shenzhen TargetRx. Inc. Solid form of macrocyclic compound, preparation therefor and use thereof
IL299732A (en) * 2020-07-10 2023-03-01 Blossomhill Therapeutics Inc Macrocycles and their use
TW202241911A (zh) * 2020-12-17 2022-11-01 美商榮山醫藥股份有限公司 大環化合物及其用途
CN114805371B (zh) * 2021-01-19 2024-05-24 江苏开元药业有限公司 含2-氨基嘧啶大环类化合物及其制备方法和用途
WO2022182845A1 (en) * 2021-02-25 2022-09-01 Blossomhill Therapeutics, Inc. Macrocycles and their use
EP4320153A1 (en) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
CN115246843A (zh) * 2021-04-26 2022-10-28 苏州东南药业股份有限公司 一类十四元稠环衍生物及其应用
CR20230586A (es) 2021-06-04 2024-05-07 Vertex Pharma N-(hydroxyalquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
US12043626B2 (en) 2021-10-01 2024-07-23 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2023156983A1 (en) 2022-02-21 2023-08-24 Universidade Nova De Lisboa Compounds and compositions for neurodegenerative diseases
EP4230201A1 (en) 2022-02-21 2023-08-23 Universidade Nova De Lisboa Composition for treating neurodegenerative diseases
WO2024086634A1 (en) * 2022-10-19 2024-04-25 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
CN115746023B (zh) * 2022-10-27 2024-08-09 复旦大学 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法
CN118434744A (zh) * 2022-12-01 2024-08-02 中国医药研究开发中心有限公司 含氮大环类化合物及其制备方法和医药用途
WO2024146541A1 (en) * 2023-01-03 2024-07-11 Guangdong Newopp Biopharmaceuticals Co., Ltd. Macrocyclic compounds as usp1 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
PT1603570E (pt) 2003-02-26 2013-03-26 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
MX2007002248A (es) 2004-08-25 2008-10-02 Pfizer Triazolobenzodiazepinas y su uso como antagonistas de vasopresina.
CN101018780B (zh) 2004-08-26 2012-01-11 辉瑞大药厂 作为蛋白激酶抑制剂的吡唑取代的氨基杂芳基化合物
AP2373A (en) * 2004-08-26 2012-03-07 Pfizer Enantiomerically pure aminoheteroaryl compounds asprotein kinase inhibitors.
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
AU2006323027B2 (en) 2005-12-05 2012-08-02 Pfizer Products Inc Method of treating abnormal cell growth
RU2387650C2 (ru) 2005-12-05 2010-04-27 Пфайзер Продактс Инк. Полиморфы с-met/hgfr ингибитора
WO2008088881A1 (en) 2007-01-19 2008-07-24 Xcovery, Inc. Kinase inhibitor compounds
PE20090110A1 (es) 2007-03-01 2009-04-04 Chugai Pharmaceutical Co Ltd Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90
KR20090110381A (ko) * 2007-03-13 2009-10-21 화이자 프로덕츠 인크. 에리트로마이신계 마크로라이드
JP2011511005A (ja) * 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
EP2274288A2 (en) * 2008-04-24 2011-01-19 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
BRPI0913349A2 (pt) * 2008-06-06 2015-11-24 Sanofi Aventis derivados de ureia e sulfamida macrocíclicos como inibidores de tafia
EP2334301B1 (en) * 2008-09-08 2018-02-14 Merck Serono SA Macrocyclics pyrimidines as aurora kinase inhibitors
US8765727B2 (en) * 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2011047926A1 (en) 2009-10-21 2011-04-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Non-natural macrocyclic amide hdac6 inhibitor compounds and their uses as therapeutic agents
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
US8916593B2 (en) * 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
SI3205654T1 (sl) * 2010-05-20 2019-07-31 Array Biopharma, Inc. Makrociklične spojine kot inhibitorji TRK kinaze
US8975232B2 (en) 2010-07-29 2015-03-10 President And Fellows Of Harvard College Macrocyclic kinase inhibitors and uses thereof
WO2012125603A1 (en) 2011-03-16 2012-09-20 Cephalon, Inc. Macrocyclic compounds as alk, fak and jak2 inhibitors

Also Published As

Publication number Publication date
EP2822953B1 (en) 2017-02-01
DOP2014000188A (es) 2014-11-16
MX350844B (es) 2017-09-22
US20140135339A1 (en) 2014-05-15
DK2822953T3 (en) 2017-04-03
SG11201404451TA (en) 2014-09-26
SI2822953T1 (sl) 2017-04-26
HUE034118T2 (en) 2018-01-29
MD4590B1 (ro) 2018-08-31
CA2863892C (en) 2016-08-30
US8680111B2 (en) 2014-03-25
KR20140137414A (ko) 2014-12-02
NO2019034I1 (no) 2019-08-19
PH12014501992A1 (en) 2014-11-24
JP2015510879A (ja) 2015-04-13
GT201400187A (es) 2015-10-15
LUC00131I1 (lt) 2019-10-11
MD4590C1 (ro) 2019-03-31
CY1118771T1 (el) 2017-07-12
CO7061081A2 (es) 2014-09-19
NI201400102A (es) 2015-03-05
JP6002825B2 (ja) 2016-10-05
KR101692600B1 (ko) 2017-01-03
EP2822953A1 (en) 2015-01-14
CY2019033I2 (el) 2019-11-27
HRP20170287T1 (hr) 2017-04-21
LT2822953T (lt) 2017-04-10
BR112014022106A2 (pt) 2017-07-11
US20130252961A1 (en) 2013-09-26
JP2016041709A (ja) 2016-03-31
TWI476199B (zh) 2015-03-11
MX2014010716A (es) 2014-09-22
JP5823066B2 (ja) 2015-11-25
MY169142A (en) 2019-02-18
CA2863892A1 (en) 2013-09-12
EA026155B9 (ru) 2017-06-30
EA026155B1 (ru) 2017-03-31
AU2013229173A1 (en) 2014-08-21
NZ627900A (en) 2016-08-26
CR20140370A (es) 2014-08-21
LTPA2019519I1 (lt) 2019-11-11
PT2822953T (pt) 2017-04-06
HK1199247A1 (zh) 2015-06-26
EA201491394A1 (ru) 2015-05-29
PL2822953T3 (pl) 2017-07-31
FR19C1062I1 (lt) 2019-11-22
FR19C1062I2 (fr) 2020-09-04
PH12014501992B1 (en) 2014-11-24
AP2014007881A0 (en) 2014-08-31
PE20142339A1 (es) 2015-01-15
CN104169286B (zh) 2016-06-08
WO2013132376A1 (en) 2013-09-12
EP2822953B9 (en) 2017-06-21
US9133215B2 (en) 2015-09-15
CL2014002084A1 (es) 2014-11-03
ZA201406244B (en) 2015-05-27
TW201350484A (zh) 2013-12-16
NL301006I2 (nl) 2020-04-14
LUC00131I2 (lt) 2020-07-16
HUS1900040I1 (hu) 2019-09-30
BR112014022106B1 (pt) 2022-08-02
DK2822953T5 (en) 2017-09-11
IL234062A (en) 2017-08-31
AR090230A1 (es) 2014-10-29
GEP201606560B (en) 2016-10-25
ME02630B (me) 2017-06-20
ES2621220T3 (es) 2017-07-03
CY2019033I1 (el) 2019-11-27
UY34657A (es) 2013-10-31
ES2621220T9 (es) 2017-11-23
AU2013229173B2 (en) 2017-06-01
RS55814B1 (sr) 2017-08-31
HRP20170287T2 (hr) 2017-11-03
CN104169286A (zh) 2014-11-26
MD20140086A2 (ro) 2015-01-31

Similar Documents

Publication Publication Date Title
LTPA2019519I1 (lt) Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
EP3038647A4 (en) Combination therapy for the treatment of glioblastoma
FI20125146A (fi) Selluloosamassan esikäsittelymenetelmä
HK1213886A1 (zh) 用於治療心血管疾病的 -哌啶- -基苯甲酰胺衍生物
DK2872497T4 (da) Chromanyl-derivater til behandling af mitokondriel sygdom
HK1225385A1 (zh) 用於治療呼吸病的雜芳基衍生物
HK1204605A1 (en) Functionalized thieno-indole derivatives for the treatment of cancer
IL237976A0 (en) A derivative of 7-azaindole-2,7-naphthyridine for the treatment of tumors
IL233493A (en) Imidazopyridine derivatives for cancer treatment
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
HK1208454A1 (zh) 治療細菌性疾病的嘧啶衍生物
HK1202118A1 (en) Piperazinyl derivatives for the treatment of cancer
TH1401005856A (th) สารอนุพันธ์ไธอีโนไพริมิดีนชนิดใหม่, กระบวนการสำหรับการเตรียมของสารนั้น และ การใช้ในเชิงบำบัดของสารนั้น
TH1501000417A (th) อนุพันธ์ของอะซาอินดาโซลหรือไดอะซาอินดาโซล ไทป์สำหรับการรักษาความเจ็บปวด